A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy. Issue 1 (22nd March 2016)

• Record Type: Journal Article
• Authors: Eng, Cathy; Bessudo, Alberto; Hart, Lowell L.; Severtsev, Aleksey; Gladkov, Oleg; Müller, Lothar; Kopp, Mikhail V.; Vladimirov, Vladimir; Langdon, Robert; Kotiv, Bogdan; Barni, Sandro; Hsu, Ching; Bolotin, Ellen; von Roemeling, Reinhard; Schwartz, Brian; Bendell, Johanna C.
• Is Part Of: International journal of cancer. Volume 139:Issue 1(2016:Jul. 01)
• Page Start: 177
• Page End: 186
• Publication Date: 2016-03-22
• Subjects: irinotecan -- KRAS wild‐type -- MET inhibitor -- metastatic colorectal cancer -- tivantinib; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.30049
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract : Cetuximab in combination with an irinotecan‐containing regimen is a standard treatment in patients with KRAS wild‐type ( KRAS WT), metastatic colorectal cancer (mCRC). We investigated the addition of the oral MET inhibitor tivantinib to cetuximab + irinotecan (CETIRI) based on preclinical evidence that activation of the MET pathway may confer resistance to anti‐EGFR therapy. Previously treated patients with KRAS WT advanced or mCRC were enrolled. The phase 1, open‐label 3 + 3, dose‐escalation study evaluated the safety and maximally tolerated dose of tivantinib plus CETIRI. The phase 2, randomized, double‐blinded, placebo‐controlled study of biweekly CETIRI plus tivantinib or placebo was restricted to patients who had received only one prior line of chemotherapy. The phase 2 primary endpoint was progression‐free survival (PFS). The recommended phase 2 dose was tivantinib (360 mg/m 2 twice daily) with biweekly cetuximab (500 mg/m 2 ) and irinotecan (180 mg/m 2 ). Among 117 patients evaluable for phase 2 analysis, no statistically significant PFS difference was observed: 8.3 months on tivantinib vs . 7.3 months on placebo (HR, 0.85; 95% confidence interval, 0.55–1.33; P = 0.38). Subgroup analyses trended in favor of tivantinib in patients with MET‐High tumors by immunohistochemistry, PTEN‐Low tumors, or those pretreated with oxaliplatin, but subgroups were too small to draw conclusions. Neutropenia, diarrhea, nausea and rash were the most frequent severe adverse events in tivantinib‐treated patients. The combination of tivantinib and CETIRI was well tolerated but did not significantly improve PFS in previously treated KRAS WT mCRC. Tivantinib may be more active in specific subgroups. Abstract : What's new? Is there a way to head off drug‐resistant colorectal cancer? A new study investigates whether a new drug, tivantinib, can improve survival by staving off tumor cells' resistance to chemotherapy. Previous results have shown that the MET signaling pathway contributes to the spread of cancer and the onset of resistance. The authors added the MET inhibitor tivantinib to the regimen of cetuximab and irinotecan. The tivantinib did not improve survival times, but the drug might yet prove effective among specific tumor subgroups.